Zobrazeno 1 - 10
of 141
pro vyhledávání: '"Cathy W, Critchlow"'
Autor:
Jie Zhang, Peter Yu, Ying Bao, Cathy W Critchlow, Corina Bennett, Fang He, Julia Zhu, Zhongyuan Wei, Qian Xia, Jenny Jiang, Olulade Ayodele, Brian D Bradbury, Corinne Brooks, Carolyn A Brown, Alvan Cheng, Giovanna Devercelli, Kathleen Gondek, Ajit A Londhe, Junjie Ma, Michele Jonsson-Funk, Hillary A Keenan, Kaili Ren, Lynn Sanders, Linyun Zhou, John H Page, J Michael Sprafka, Megan Braunlin, Prista Charuworn, Karminder Gill, Jeffrey Petersen, Katherine B Carlson, Shun-Chiao Chang, Kimberly A Roehl, Luyang Wang
Publikováno v:
BMJ Open, Vol 12, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/8d862731349f4c36b3e1599111849ac7
Autor:
Jie Zhang, Peter Yu, Sudhakar Manne, Ying Bao, Cathy W Critchlow, Julia Zhu, Zhongyuan Wei, Manasi Suryavanshi, Xiu Chen, Qian Xia, Jenny Jiang, Olulade Ayodele, Brian D Bradbury, Corinne Brooks, Carolyn A Brown, Alvan Cheng, Giovanna Devercelli, Vivek Gandhi, Kathleen Gondek, Ajit A Londhe, Junjie Ma, Michele Jonsson-Funk, Hillary A Keenan, Kaili Ren, Lynn Sanders, Linyun Zhou
Publikováno v:
BMJ Open, Vol 11, Iss 8 (2021)
Objective To examine age, gender, and temporal differences in baseline characteristics and clinical outcomes of adult patients hospitalised with COVID-19.Design A cohort study using deidentified electronic medical records from a Global Research Netwo
Externí odkaz:
https://doaj.org/article/0e3c644e58f9442c8c9f5cc25b1c4819
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-6 (2018)
Abstract Background Post-marketing safety studies of medicines often rely on administrative claims databases to identify adverse outcomes following drug exposure. Valid ascertainment of outcomes is essential for accurate results. We aim to quantify t
Externí odkaz:
https://doaj.org/article/211f7c945ed043f794998b514e67f2ec
Autor:
Michael D. Blum, Wei Zhou, Mehmet Burcu, Eleanor M. Perfetto, Cathy W. Critchlow, Jessica M. Franklin, Nancy A Dreyer
Publikováno v:
Pharmacoepidemiology and Drug Safety
Randomized clinical trials (RCTs) are the gold standard in producing clinical evidence of efficacy and safety of medical interventions. More recently, a new paradigm is emerging—specifically within the context of preauthorization regulatory decisio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9e67789384e311afcbdfe8a3ab511f
http://europepmc.org/articles/PMC7687199
http://europepmc.org/articles/PMC7687199
Autor:
Wen Chang, Steven K. Galson, Neal E. Storm, Brian D. Bradbury, Tzu-Chieh Lin, Jeff Lange, Cathy W. Critchlow
Publikováno v:
Therapeutic Innovation & Regulatory Science
On June 23, 2020, Prolia® (denosumab) was approved by the National Medical Products Administration (NMPA) in the People’s Republic of China as the first monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d060c34d2eac7eab9014c139ca1afb29
https://pubmed.ncbi.nlm.nih.gov/34633649
https://pubmed.ncbi.nlm.nih.gov/34633649
Publikováno v:
Patterns
Summary Thanks to the increasing availability of genomics and other biomedical data, many machine learning algorithms have been proposed for a wide range of therapeutic discovery and development tasks. In this survey, we review the literature on mach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63ded04c943a6ed70b49dcf04dadf933
http://arxiv.org/abs/2105.01171
http://arxiv.org/abs/2105.01171
Publikováno v:
Pharmacoepidemiology and drug safetyREFERENCES. 30(6)
There is increasing interest in utilizing real-world data (RWD) to produce real-world evidence (RWE) on the benefits and risks of medical products that could support regulatory approval decisions. The field of pharmacoepidemiology has a long history
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d91a8c3c3765d59ca5d8ce4528957aae
https://pubmed.ncbi.nlm.nih.gov/33675248
https://pubmed.ncbi.nlm.nih.gov/33675248
Autor:
John H Page, Ajit A Londhe, Corinne Brooks, Jie Zhang, J Michael Sprafka, Corina Bennett, Megan Braunlin, Carolyn A Brown, Prista Charuworn, Alvan Cheng, Karminder Gill, Fang He, Junjie Ma, Jeffrey Petersen, Olulade Ayodele, Ying Bao, Katherine B Carlson, Shun-Chiao Chang, Giovanna Devercelli, Michele Jonsson-Funk, Jenny Jiang, Hillary A Keenan, Kaili Ren, Kimberly A Roehl, Lynn Sanders, Luyang Wang, Zhongyuan Wei, Qian Xia, Peter Yu, Linyun Zhou, Julia Zhu, Kathleen Gondek, Cathy W Critchlow, Brian D Bradbury
Publikováno v:
BMJ Open. 12:e055137
ObjectivesTo examine the temporal patterns of patient characteristics, treatments used and outcomes associated with COVID-19 in patients who were hospitalised for the disease between January and 15 November 2020.DesignObservational cohort study.Setti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e07817f1e81d64fb32d4affa4448c2a7
https://doi.org/10.1136/bmjopen-2021-055137
https://doi.org/10.1136/bmjopen-2021-055137
Autor:
Kathleen Gondek, Corinne G. Brooks, Ajit A. Londhe, Giovanna Devercelli, Qian Xia, Brian D. Bradbury, Zhongyuan Wei, Xiu Chen, Ying Bao, Linyun Zhou, Kaili Ren, Hillary A Keenan, Peter Yu, Olulade Ayodele, Lynn Sanders, Michele Jonsson-Funk, Junjie Ma, Jie Zhang, Alvan Cheng, Manasi Suryavanshi, Cathy W. Critchlow, Jenny Jiang, Julia Zhu, Vivek Gandhi, Carolyn A. Brown, Sudhakar Manne
Publikováno v:
BMJ Open, Vol 11, Iss 8 (2021)
BMJ Open
BMJ Open
ObjectiveTo examine age, gender, and temporal differences in baseline characteristics and clinical outcomes of adult patients hospitalised with COVID-19.DesignA cohort study using deidentified electronic medical records from a Global Research Network
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afe897849b583c229cbf3e81a02922e
https://doi.org/10.1136/bmjopen-2021-051588
https://doi.org/10.1136/bmjopen-2021-051588
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-6 (2018)
BMC Health Services Research
BMC Health Services Research
Background Post-marketing safety studies of medicines often rely on administrative claims databases to identify adverse outcomes following drug exposure. Valid ascertainment of outcomes is essential for accurate results. We aim to quantify the validi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f92b2ed100951cc21a650e1848eedbb
https://doi.org/10.1186/s12913-018-3016-y
https://doi.org/10.1186/s12913-018-3016-y